Nothing Special   »   [go: up one dir, main page]

SG11202109463PA - Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof - Google Patents

Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof

Info

Publication number
SG11202109463PA
SG11202109463PA SG11202109463PA SG11202109463PA SG 11202109463P A SG11202109463P A SG 11202109463PA SG 11202109463P A SG11202109463P A SG 11202109463PA SG 11202109463P A SG11202109463P A SG 11202109463PA
Authority
SG
Singapore
Prior art keywords
methyl
ethylpiperazin
indazol
pyrimidin
fluoro
Prior art date
Application number
Inventor
Michael Greco
Michael Costanzo
Jirong Peng
Don Zhang
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of SG11202109463PA publication Critical patent/SG11202109463PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202109463P 2019-03-20 2020-03-20 Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof SG11202109463PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821141P 2019-03-20 2019-03-20
PCT/US2020/023828 WO2020191283A1 (en) 2019-03-20 2020-03-20 Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
SG11202109463PA true SG11202109463PA (en) 2021-10-28

Family

ID=72519375

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109463P SG11202109463PA (en) 2019-03-20 2020-03-20 Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof

Country Status (9)

Country Link
US (1) US20220162185A1 (en)
EP (1) EP3941472B1 (en)
JP (1) JP2022525780A (en)
CN (1) CN113840605B (en)
AU (1) AU2020240301A1 (en)
IL (1) IL286012A (en)
SG (1) SG11202109463PA (en)
TW (1) TW202102487A (en)
WO (1) WO2020191283A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191938A1 (en) * 2019-01-29 2021-10-13 Бета Фарма, Инк. 2H-INDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS FOR BRAIN CANCER AND BRAIN METASTASIS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202004716RA (en) * 2014-07-24 2020-06-29 Beta Pharma Inc 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
RU2722363C2 (en) * 2015-03-11 2020-05-29 Чиа Тай Тяньцинь Фармасьютикал Груп Ко., Лтд. Substituted 2h-pyrazole derivative
WO2018045993A1 (en) * 2016-09-09 2018-03-15 正大天晴药业集团股份有限公司 Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor

Also Published As

Publication number Publication date
JP2022525780A (en) 2022-05-19
TW202102487A (en) 2021-01-16
WO2020191283A1 (en) 2020-09-24
EP3941472B1 (en) 2024-07-10
EP3941472A4 (en) 2023-03-15
US20220162185A1 (en) 2022-05-26
AU2020240301A1 (en) 2021-09-23
IL286012A (en) 2021-10-31
EP3941472A1 (en) 2022-01-26
CN113840605A (en) 2021-12-24
CN113840605B (en) 2024-05-28

Similar Documents

Publication Publication Date Title
IL272444B (en) Phenyl and heteroaryl derivatives of (1-substituted-piperidin-4- yl)urea, salts thereof and their use for treatment of diseases
IL287030A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CY1124078T1 (en) COMPOSITIONS COMPRISING LYSINE-SPECIFIC DEMETHYLASE-1 INHIBITOR HAVING A PYRIMIDINE RING AND USE THEREOF IN THE TREATMENT OF CANCER
EA201992300A1 (en) CRYSTAL FORM 6- (CYCLOPROPANOCARBOXAMIDO) -4 - ((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL) Phenyl) AMINO) -N- (METHYL-d3) Pyridazine -3-CARBOXAMIDE
IL288508A (en) N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
MY179802A (en) Hydrochloride salt form for ezh2 inhibition
NZ725966A (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
EP3807279A4 (en) Pharmaceutically acceptable salts of sepiapterin
MX2021002255A (en) Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021006552A (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia.
TW201613931A (en) Form crystal of bisulfate of janus kinase (JAK) inhibitor and preparation method thereof
NZ719688A (en) Pesticidal compositions and related methods
IL286012A (en) Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
IL276430A (en) Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same
HK1254731A1 (en) Novel crystalline salt forms of 3-(1,2,4-triazolo[4,3-a]pyridine-3-ylethynyl)-4-methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)benzamide for medical application
MX2020005332A (en) Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production.
SG11201604517WA (en) Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
ZA202101652B (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
EP3471730A4 (en) Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
EP4013422A4 (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
EP3740484A4 (en) 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
UA116804C2 (en) Herbicidally active 2-(substituted-phenyl)-cyclopentane-1,3-dione compounds and derivatives thereof
WO2015009882A3 (en) Cyano derivatives and their uses
PH12018501314A1 (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound
ZA202008062B (en) Pharmaceutically acceptable salts of sepiapterin